The mission of Dxcover® is to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. A University of Strathclyde spin-out, its first product will rapidly fast-track patients with suspected brain tumours for further treatment saving months of GP visits and specialist scans.
Dxcover has conducted clinical trials with its ‘drop, dry, detect’ technology. To advance commercial plans, the team wanted to create a single platform capable of handling data from laboratories across the world.
Dxcover is using Lumen® to accelerate the delivery of its cancer diagnostic system for clinical blood samples. The efficiency savings that Lumen provides will enable quicker and more economic clinical trials as Dxcover builds towards a globally available, cloud hosted product.